Generation and characterization of a bivalent HIV-1 subtype c gp120 protein boost for proof-of-concept HIV vaccine efficacy trials in southern Africa

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Zambonelli, Carlo ^a   Dey, Antu K ^a,e   Hilt, Susan ^a   Stephenson, Samuel ^a   Go, Eden P ^b   Clark, Daniel F ^b   Wininger, Mark ^a   Labranche, Celia ^c   Montefiori, David ^c   Liao, Hua Xin ^c   Swanstrom, Ronald I ^d   Desaire, Heather ^b   Haynes, Barton F ^c   Carfi, Andrea ^a   Barnett, Susan W Barnett ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; DISULFIDE; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; ANTISERUM; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CHO CELL LINE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IMMUNOGENICITY; MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; SOUTH AFRICA; VIRUS NEUTRALIZATION; VIRUS STRAIN; AFRICA; ANIMAL; BLOOD; CRICETULUS; FEMALE; GLYCOSYLATION; HAMSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PROTEIN MULTIMERIZATION; RABBITS AND HARES; TREATMENT OUTCOME; VIROLOGY;

AFRICA, SOUTHERN; AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CLINICAL TRIALS AS TOPIC; CRICETINAE; CRICETULUS; DISULFIDES; EPITOPES; FEMALE; GLYCOSYLATION; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNE SERA; PROTEIN MULTIMERIZATION; RABBITS; TREATMENT OUTCOME;

EID: 84979600127     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157391     Document Type: Article

References (47)

1. Van Harmelen JH, Van der Ryst E, Loubser AS, York D, Madurai S, Lyons S, et al. A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS research and human retroviruses. 1999; 15(4):395-8. doi: 10.1089/088922299311376 PMID: 10082124.
2. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. Aids. 2006; 20(16):W13-23. doi: 10.1097/01.aids.0000247564.73009.bc PMID: 17053344.
3. Andrews S. Access to essential medications for HIV/AIDS in South Africa. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2001; 91(5):384-7. PMID: 11455797.
4. Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. Journal of acquired immune deficiency syndromes. 2002; 29(2):132-41. PMID: 11832681.
5. Fauci AS, Marston HD. Ending AIDS-is an HIV vaccine necessary? The New England journal of medicine. 2014; 370(6):495-8. doi: 10.1056/NEJMp1313771 PMID: 24499210.
6. Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, de Souza M, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. The Journal of infectious diseases. 2003; 188(2):219-27. doi: 10.1086/376506 PMID: 12854076.
7. Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, et al. Phase I/ II study of a candidate vaccine designed against the B and E subtypes of HIV-1. Journal of acquired immune deficiency syndromes. 2004; 37(1):1160-5. PMID: 15319676.
8. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. Journal of acquired immune deficiency syndromes. 2004; 37(3):1385-92. PMID: 15483468.
9. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Annals of internal medicine. 1996; 125 (4):270-9. PMID: 8678389.
10. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. The Journal of infectious diseases. 2005; 191(5):654-65. doi: 10.1086/428404 PMID: 15688278.
11. Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology. 1999; 265(1):1-9. doi: 10.1006/viro.1999.0031 PMID: 10603312.
12. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. The Journal of infectious diseases. 2005; 191(5):666-77. doi: 10.1086/428405 PMID: 15688279.
13. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. The Journal of infectious diseases. 2006; 194(12):1661-71. doi: 10.1086/508748 PMID: 17109337.
14. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3PMID: 19012954; PubMed Central PMCID: PMC2721012.
15. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). The Journal of infectious diseases. 2012; 206(2):258-66. doi: 10.1093/infdis/jis342 PMID: 22561365; PubMed Central PMCID: PMC3490694.
16. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. The New England journal of medicine. 2013; 369(22):2083-92. doi: 10.1056/NEJMoa1310566 PMID: 24099601; PubMed Central PMCID: PMC4030634.
17. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of medicine. 2009; 361(23):2209-20. PMID: 19843557 doi: 10.1056/NEJMoa0908492
18. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. The Lancet Infectious diseases. 2012; 12(7):531-7. doi: 10.1016/S1473-3099(12)70088-9 PMID: 22652344; PubMed Central PMCID: PMC3530398.
19. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England journal of medicine. 2012; 366(14):1275-86. doi: 10.1056/NEJMoa1113425 PMID: 22475592; PubMed Central PMCID: PMC3371689.
20. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490(7420):417-20. doi: 10.1038/nature11519 PMID: 22960785; PubMed Central PMCID: PMC3551291.
21. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science translational medicine. 2014; 6(228):228ra39. doi: 10.1126/scitranslmed.3007730 PMID: 24648342; PubMed Central PMCID: PMC4116665.
22. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Science translational medicine. 2014; 6(228):228ra38. doi: 10.1126/scitranslmed.3007736 PMID: 24648341.
23. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013; 342(6165):1477-83. doi: 10.1126/science.1245625 PMID: 24179159; PubMed Central PMCID: PMC3886632.
24. Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, et al. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. Journal of virology. 2002; 76(6):2835-47. PMID: 11861851; PubMed Central PMCID: PMC135955.
25. Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K, et al. Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. PLoS One. 2012; 7(1):e30233. PMID: 22291921 doi: 10.1371/journal.pone.0030233
26. Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, et al. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology. 2008; 372 (1):187-200. PMID: 18031785.
27. Go EP, Hewawasam G, Liao HX, Chen H, Ping LH, Anderson JA, et al. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. Journal of virology. 2011; 85(16):8270-84. PMID: 21653661 doi: 10.1128/JVI.05053-11
28. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of virology. 2005; 79(16):10108-25. PMID: 16051804.
29. Montefiori D. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. and Coico R., Editors, ?ÄúCurrent Protocols in Immunology?Äù, John Wiley & Sons, New York, NY (2004), 2004. 12.1.1 ?Äì.1.5. p.
30. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Prasad Vinayaka R. K GV, eds., editor: Humana Press; 2009. 395-405 p.
31. Engelbrecht S, de Villiers T, Sampson CC, zur Megede J, Barnett SW, van Rensburg EJ. Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa. AIDS research and human retroviruses. 2001; 17(16):1533-47. doi: 10.1089/08892220152644241 PMID: 11709098.
32. Lian Y, Srivastava I, Gomez-Roman VR, Zur Megede J, Sun Y, Kan E, et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. Journal of virology. 2005; 79(21):13338-49. doi: 10.1128/JVI.79.21.13338-13349.2005 PMID: 16227256; PubMed Central PMCID: PMC1262580.
33. Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N, Ma BJ, et al. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. Journal of virology. 2013; 87(8):4185-201. PMID: 23365441 doi: 10.1128/JVI.02297-12
34. Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao HX, Sutherland LL, et al. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res. 2008; 7(4):1660-74. PMID: 18330979 doi: 10.1021/pr7006957
35. Clark DF, Go EP, Desaire H. Simple approach to assign disulfide connectivity using extracted ion chromatograms of electron transfer dissociation spectra. Analytical chemistry. 2013; 85(2):1192-9. doi: 10. 1021/ac303124w PMID: 23210856; PubMed Central PMCID: PMC3607449.
36. Go EP, Hua D, Desaire H. Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation. J Proteome Res. 2014; 13(9):4012-27. doi: 10.1021/pr5003643 PMID: 25026075; PubMed Central PMCID: PMC4156237.
37. Go EP, Zhang Y, Menon S, Desaire H. Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 DeltaCFI shows variability in the V1 and V2 regions. J Proteome Res. 2011; 10(2):578-91. doi: 10.1021/pr100764a PMID: 21114338; PubMed Central PMCID: PMC3075074.
38. Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, et al. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. PLoS One. 2013; 8(10):e76139. doi: 10.1371/journal.pone.0076139 PMID: 24146829; PubMed Central PMCID: PMC3797752.
39. Finzi A, Pacheco B, Zeng X, Kwon YD, Kwong PD, Sodroski J. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods. 2010; 168(1-2):155-61. PMID: 20471426 doi: 10.1016/j.jviromet.2010.05.008
40. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Human vaccines. 2008; 4 (5):347-9. PMID: 18682690.
41. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharmaceutical biotechnology. 1995; 6:277-96. PMID: 7551221.
42. Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, et al. Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS pathogens. 2015; 11(3):e1004767. doi: 10. 1371/journal.ppat.1004767 PMID: 25807248; PubMed Central PMCID: PMC4373910.
43. Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, Mao Y, et al. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. Journal of virology. 2015; 89(16):8245-57. doi: 10.1128/JVI.00628-15 PMID: 26018173; PubMed Central PMCID: PMCPMC4524223.
44. Garcia-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, et al. Head-tohead comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime/boost combination with Env protein in non-human primates. Journal of virology. 2015. doi: 10.1128/JVI.01265-15 PMID: 26041302.
45. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014; 9(2):e87572. doi: 10.1371/journal.pone.0087572 PMID: 24504509; PubMed Central PMCID: PMC3913641.
46. Sharma SK, de Val N, Bale S, Guenaga J, Tran K, Feng Y, et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell reports. 2015; 11(4):539-50. doi: 10.1016/j.celrep.2015.03.047 PMID: 25892233; PubMed Central PMCID: PMC4637274.
47. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013; 342(6165):1484-90. doi: 10.1126/ science.1245627 PMID: 24179160; PubMed Central PMCID: PMC3954647.